Moderna Announces Update to 2022 Supply Agreement with Gavi that Secures Access to Updated Variant-Specific COVID-19 Vaccines for Low-and-Middle Income Countries
yahoo.com
news
2022-10-17 10:00:00

Given the sufficient supply of COVID-19 vaccines globally, Moderna & Gavi have mutually agreed to cancel remaining pending orders under the current COVID-19 vaccine supply agreement for 2022

Gavi and Moderna have agreed to create a new framework that would enable Gavi to purchase up to 100 million doses of updated variant-specific COVID-19 vaccines in 2023, with all doses offered at Moderna's lowest-tiered price

CAMBRIDGE, MA / ACCESSWIRE / October 17, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Gavi, the Vaccine Alliance, have mutually agreed to cancel remaining pending orders under the current COVID-19 vaccine supply agreement for 2022.
